Article

Forbes on 2021-07-09 19:49

FDA Commissioner Calls For Inspector General Probe Into Biogen Alzheimer’s Drug Approval

The investigation comes after journalists reported improper back channel communications between Biogen and FDA officials.

Related news

MFDA chief tells reporters “transfer on” when pushing for approval of Biogen Alzheimer’s mvtelegraph.com
Wall Street , Massachusetts , Cambridge
House investigation faults FDA, Biogen for Alzheimer’s drug approval post-gazette.com
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approval observer.com
FFDA approves Biogen Alzheimer’s drug ft.com
BAfter Lengthy Delay, Biogen Submits Troubled Alzheimer’s Drug for FDA Approval barrons.com
Stock Island
FDA calls for federal investigation into approval of Alzheimer’s drug New York Post
FDA to Probe Communications Between Staff and Biogen on Alzheimer’s Drug wsj.com
Cambridge
Panels find FDA, Biogen rushed Alzheimer’s drug Arkansas Online
Philadelphia , Cambridge
FBiogen to seek Alzheimer’s drug approval ft.com
BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 min barrons.com
BBiogen Stock Jumps on FDA Approval barrons.com
Wall Street , Mount Sinai , Unmet
Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake Forbes
BA Crucial FDA Hearing Looms for Biogen Alzheimer’s Drug barrons.com
Wall Street
FDA head calls for investigation into agency approval of Alzheimer’s drug Alaska Dispatch News
Three experts resign as FDA advisors over approval of Alzheimer’s drug Ars Technica
Axios , Minnesota , Brigham City , Maryland , White Oak
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal Ars Technica
Phase 4 , Switzerland , Massachusetts , Cambridge
Manchin Wants Biden To Oust FDA Chief Over Controversial Alzheimer’s Drug Approval Forbes
White House
Doctors blast Biogen Alzheimer’s drug approval as ‘regulatory failure’Star Telegram
Bristol , San Francisco , Mayo Clinic , Cambridge